Burundi vs Cambodia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Burundi
0.4%
in 2024
Cambodia
0.4%
in 2024
Burundi rank
59th
Cambodia rank
59th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Burundi
- Cambodia
How they compare
Burundi currently reports 0.4% against 0.4% in Cambodia, a difference of 0.0%.
Across all 10 years both countries report, Cambodia has been ahead every year.
Burundi ranks 59th and Cambodia ranks 59th of 215 countries.
Head to head by decade
| Decade | Burundi | Cambodia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.4% | 0.4% | 0.0% | — |
| 2020s | 0.4% | 0.4% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Burundi or Cambodia?
- Burundi, at 0.4% against 0.4% in Cambodia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Burundi and Cambodia?
- 0.0%, with Burundi ahead.
- How many years of comparable data are there for Burundi and Cambodia?
- 10 years are reported by both, from 2015 to 2024.
- How do Burundi and Cambodia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Burundi ranks 59th and Cambodia ranks 59th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.